Prevention of human PC-346C prostate cancer growth in mice by a xenogeneic tissue vaccine

Cancer Immunology, Immunotherapy

Volumn 56, Issue 8, 2007, Pages 1275-1283

  Suckow, Mark A ^a   Rosen, Elliot D ^b   Wolter, William R ^a   Sailes, Valerie ^a   Jeffrey, Randy ^a   Tenniswood, Martin ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CANCER VACCINE; CYTOKINE; GAMMA INTERFERON; GLUTARALDEHYDE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CANCER CELL CULTURE; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER PREVENTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; MALE; MOUSE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; SPLEEN; SPLEEN CELL; TH2 CELL; WISTAR RAT; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOKINES; DISEASE PROGRESSION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMMUNOTHERAPY, ACTIVE; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; ORGAN SIZE; PROSTATIC NEOPLASMS; SPLEEN; T-LYMPHOCYTE SUBSETS; TUMOR BURDEN; VACCINATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34248573627     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-006-0278-8     Document Type: Article

References (61)

1. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, Schrag D, Jamison PM, Jemal A, Wu XC, Friedman C, Harlan L, Warren J, Anderson RN, Pickle LW (2005) Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97(19):1407-1427
2. Greenlee RT, Harmon MB, Murray T, Thun M (2001) Cancer statistics. CA Cancer J Clin 51:15-36
3. Bosland MC (1996) Hormonal factors in carcinogenesis of the prostate and testis in humans and in animal models. In: Huff J, Boyd J, Barrett JC (eds) Cellular and molecular mechanisms of hormonal carcinogenesis: environmental influences. Wiley-Liss, Hoboken, pp 309-352
4. Hellerstedt BA, Pienta KJ (2002) The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52(3):154-179
5. Hudes GR, Greenberg R, Krigel RL, Fox S, Scher R, Litwin SL, Watts P, Speicher L, Tew K, Comis R (1992) Phase II study of estramustine and vinblastine, two microtubule inhibitors in hormone refractory prostate cancer. J Clin Oncol 10(11):1754-1761
6. Pienta KJ, Redman BG, Bandekar R, Strawderman M, Cease K, Esper PS, Naik H, Smith DC (1997) A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology 50(3):501-506
7. Hudes GR, Nathan F, Khater C, Haas N, Cornfield M, Giantonio B, Greenberg R, Gomella L, Litwin S, Ross E, Roethke S, McAleer C (1997) Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 15(9):3156-3163
8. Rumohr JA, Chang SS (2006) Current chemotherapeutic approaches for androgen-independent prostate cancer. Curr Opin Investig Drugs 7(6):529-533
9. Figg WD, Dahut W, Duray P, Hamilton M, Tompkins P, Steinberg SM (2001) A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 7(7):1888-1893
10. Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, Beetham P, Tsang KY, Grosenbach DW, Feldman J, Steinberg SM, Jones E, Chen C, Marte J, Schlom J, Dahut W (2006) A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 12(4):1260-1269
11. Murphy GP, Tjoa BA, Simmons SJ, Ragde H, Rogers M, Elgamal A, Troychak MG, Salgaller ML, Boynton AL (1999) Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 39(1):54-59
12. Murphy GP, Tjoa BA, Simmons SJ, Jarisch J, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL (1999) Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 38(1):73-78
13. Lodge PA, Jones LA, Bader RA, Murphy GP, Salgaller ML (2000) Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res 60(4):829-833
14. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH (2000) Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18(23):3894-3903
15. Rini BI (2002) Technology evaluation: APC-8015, Dendreon. Curr Opin Mol Ther 4(1):76-79
16. Correale P, Walmsley K, Zaremba S, Zhu M, Schlom J, Tsang KY (1998) Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. J Immunol 161(6):3186-3194
17. Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, Tsang K, Panicali D, Poole D, Schlom J, Michael Hamilton J (2002) Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 53(2):109-117
18. Tjoa BA, Murphy GP (2000) Development of dendritic-cell based prostate cancer vaccine. Immunol Lett 74(1):87-93
19. Tjoa BA, Simmons SJ, Elgamal A, Rogers M, Ragde H, Kenny GM, Troychak MJ, Boynton AL, Murphy GP (1999) Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 40(2):125-129
20. Tarassoff CP, Arlen PM, Gulley JL (2006) Therapeutic vaccines for prostate cancer. Oncologist 11(5):451-462
21. Lowy DR, Schiller JT (2006) Prophylactic human papillomavirus vaccines. J Clin Invest 116(5):1167-1173
22. Suckow MA, Wolter WR, Pollard M (2005) Prevention of de novo prostate cancer by immunization with tumor-derived vaccines. Cancer Immunol Immunother 54(6):571-576
23. Pollard M, Luckert PH (1975) Transplantable, metastasizing adenocarcinomas in rats. J Natl Cancer Inst 54(3):643-649
24. National Research Council (1996) Guide for the care and use of laboratory animals. National Academy, Washington, DC
25. Suwa T, Nyska A, Peckham JC, Hailey JR, Mahler JF, Haseman JK, Maronpot RR (2001) A retrospective analysis of background lesions and tissue accountability for male accessory sex organs in Fischer-344 rats. Toxicol Pathol 29(4):467-478
26. Ringler DH, Peter GK, Chrisp CE, Keren DF (1985) Protection of rabbits against experimental pasteurellosis by vaccination with a potassium thiocyanate extract of Pasteurella multocida. Infect Immun 49(3):498-504
27. Suckow MA, Chrisp CE, Foged NT (1991) Heat-labile toxin-producing isolates of Pasteurella multocida from rabbits. Lab Anim Sci 41(2):151-156
28. Su Z, Dannull J, Yang BK, Dahm P, Coleman D, Yancey D, Sichi S, Niedzwiecki D, Boczkowski D, Gilboa E, Vieweg J (2005) Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 174(6):3798-3807
29. Vieweg J, Rosenthal FM, Bannerji R, Heston WD, Fair WR, Gansbacher B, Gilboa E (1994) Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 54(7):1760-1765
30. Sanda MG, Ayyagari SR, Jaffee EM, Epstein JI, Clift SL, Cohen LK, Dranoff G, Pardoll DM, Mulligan RC, Simons JW (1994) Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 151(3):622-628
31. Moody DB, Robinson JC, Ewing CM, Lazenby AJ, Isaacs WB (1994) Interleukin-2 transfected prostate cancer cells generate a local antitumor effect in vivo. Prostate 24(5):244-251
32. Eaton JD, Perry MJ, Nicholson S, Guckian M, Russell N, Whelan M, Kirby RS (2002) Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer. BJU Int 89(1):19-26
33. Pandha HS, John RJ, Hutchinson J, James N, Whelan M, Corbishley C, Dalgleish AG (2004) Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study. BJU Int 94(3):412-418
34. Michael A, Ball G, Quatan N, Wushishi F, Russell N, Whelan J, Chakraborty P, Leader D, Whelan M, Pandha H (2005) Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res 11(12):4469-4478
35. Sebzda E, Mariathasan S, Ohteki T, Jones R, Bachmann MF, Ohashi PS (1999) Selection of the T cell repertoire. Annu Rev Immunol 17:829-874
36. Wei YQ (2002) Immunotherapy of tumors with vaccines based on xenogeneic homologous molecules. Anticancer Drugs 13(3):229-235
37. Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y, Kang B, Lu CJ, Huang MJ, Lou YY, Xiao F, He QM, Shu JM, Xie XJ, Mao YQ, Lei S, Luo F, Zhou LQ, Liu CE, Zhou H, Jiang Y, Peng F, Yuan LP, Li Q, Wu Y, Liu JY (2000) Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 6(10):1160-1166
38. Wei YQ, Huang MJ, Yang L, Zhao X, Tian L, Lu Y, Shu JM, Lu CJ, Niu T, Kang B, Mao YQ, Liu F, Wen YJ, Lei S, Luo F, Zhou LQ, Peng F, Jiang Y, Liu JY, Zhou H, Wang QR, He QM, Xiao F, Lou YY, Xie XJ, Li Q, Wu Y, Ding ZY, Hu B, Hu M, Zhang W (2001) Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci USA 98(20):11545-11550
39. Lou YY, Wei YQ, Yang L, Zhao X, Tian L, Lu Y, Wen YJ, Liu F, Huang MJ, Kang B, Xiao F, Su JM, He QM, Xie XJ, Mao YQ, Lei S, Liu JY, Lou F, Zhou LQ, Peng F, Jiang Y, Hu B (2002) Immunogene therapy of tumors with a vaccine based on the ligand-binding domain of chicken homologous integrin beta3. Immunol Invest 31(1):51-69
40. He QM, Wei YQ, Tian L, Zhao X, Su JM, Yang L, Lu Y, Kan B, Lou YY, Huang MJ, Xiao F, Liu JY, Hu B, Luo F, Jiang Y, Wen YJ, Deng HX, Li J, Niu T, Yang JL (2003) Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. J Biol Chem 278(24):21831-21836
41. Naftzger C, Takechi Y, Kohda H, Hara I, Vijayasaradhi S, Houghton AN (1996) Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci USA 93(25):14809-14814
42. Disis ML, Shiota FM, Cheever MA (1998) Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for 'self' tumour antigens. Immunology 93(2):192-199
43. Bergman PJ, McKnight J, Novosad A, Charney S, Farrelly J, Craft D, Wulderk M, Jeffers Y, Sadelain M, Hohenhaus AE, Segal N, Gregor P, Engelhorn M, Riviere I, Houghton AN, Wolchok JD (2003) Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 9(4):1284-1290
44. Liao JC, Gregor P, Wolchok JD, Orlandi F, Craft D, Leung C, Houghton AN, Bergman PJ (2006) Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun 6:8-14
45. Zhong Z, Kusznieruk KP, Popov IA, Riordan NH, Izadi H, Yijian L, Sher S, Szczurko OM, Agadjanyan MG, Tullis RH, Harandi A, Reznik BN, Mamikonyan GV, Ichim TE (2006) Induction of antitumor immunity through xenoplacental immunization. J Transl Med 4:22
46. Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL, Engleman EG (2001) Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 167(12):7150-7156
47. Hu B, Wei YQ, Tian L, Zhao X, Lu Y, Wu Y, Yao B, Zhang XW (2006) Human T lymphocyte responses against lung cancer induced by recombinant truncated mouse EGFR. Cancer Immunol Immunother 55(4):386-393
48. Takita H, Minowada J, Han T, Takada M, Lane WW (1976) Adjuvant immunotherapy in bronchogenic carcinoma. Ann NY Acad Sci 277:345-354
49. Tarassoff CP, Arlen PM, Gulley JL (2006) Therapeutic cancer vaccines for prostate cancer. Oncologist 11(5):451-462
50. Kirman I, Asi Z, Carter J, Fowler R, Whelan RL (2002) Combined whole tumor cell and monophosphoryl lipid A vaccine improved by encapsulation in murine colorectal cancer. Surg Endosc 16(4):654-658
51. Simons JW, Sacks N (2006) Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX® vaccine for prostate cancer. Urol Oncol 24(5):419-424
52. Berd D, Murphy G, Maguire HC Jr, Mastrangelo MJ (1991) Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases. Cancer Res 51(10):2731-2734
53. Fukino K, Shen L, Matsumoto S, Morrison CD, Mutter GL, Eng C (2004) Combined total genome loss of heterozygosity scan of breast cancer stroma and epithelium reveals multiplicity of stromal targets. Cancer Res 64(20):7231-7236
54. Bissell MJ, Barcellos-Hoff MH (1987) The influence of extracellular matrix on gene expression: is structure the message? J Cell Sci Suppl 8(3):327-343
55. Matrisian LM, Cunha GR, Mohla S (2001) Epithelial-stromal interactions and tumor progression: meeting summary and future directions. Cancer Res 61(9):3844-3846
56. Shekhar MP, Werdell J, Santner SJ, Pauley RJ, Tait L (2001) Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. Cancer Res 61(4):1320-1326
57. Schor SL, Schor AM (2001) Phenotypic and genetic alterations in mammary stroma: implications for tumour progression. Breast Cancer Res 3(6):373-379
58. Haslam SZ, Woodward TL (2003) Host microenvironment in breast cancer development: epithelial-cell-stromal-cell interactions and steroid hormone action in normal and cancerous mammary gland. Breast Cancer Res 5(4):208-215
59. Singh S, Ross SR, Acena M, Rowley DA, Schreiber H (1992) Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J Exp Med 175(1):139-146
60. Tatenhorst L, Puttmann S, Senner V, Paulus W (2005) Genes associated with fast glioma cell migration in vitro and in vivo. Brain Pathol 15(1):46-54
61. Moschella F, Catanzaro RP, Bisikirska B, Sawczuk IS, Papadapoulos KP, Ferrante AW Jr, McKiernan JM, Hesdorffer CS, Harris PE, Maffei A (2003) Shifting gene expression profiles during ex vivo culture of renal tumor cells: implications for cancer immunotherapy. Oncol Res 14(3):133-145